ClinicalTrials.gg
RecruitingNCT04434781G-POEMUpdated Feb 18, 2026

Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastroparesis

An observational study in Gastroparesis, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Indiana University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2018; still recruiting 8 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Gastroparesis by Indiana University — 7 open to participants now, 8 under way, none of them phase 3. Gastroparesis · Indiana University.

Started
2018
the only one that year
Observational
7 of 15
4 open now
Registered
6th of 15
by date

Among the 15 studies in Gastroparesis by Indiana University, this one is the only one that started in 2018, is one of 7 observational ones, and was the 6th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

7 of the 15 studies in Gastroparesis by Indiana University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Gastroparesis by Indiana University, or all of them as a file.
02

Study summary

Gastric Per-Oral Endoscopic Myotomy (G-POEM) is a procedure for the Treatment of Gastroparesis.

Read the detailed description

Gastroparesis is a disease of the stomach where there is significant delay in gastric emptying of contents to the intestines. This disease results in a multitude of symptoms including nausea, vomiting, weight loss, and malnutrition.

Current treatments for gastroparesis include dietary changes, oral medications (prokinetic agents to enhance gastric motility, acid reducers, anti-emetics to reduce nausea and vomiting), gastric stimulators and rarely surgery.

G-POEM (Gastric Per-Oral Endoscopic Myotomy-creating a cut in the muscle that controls gastric emptying), an incision-less (no cutting of the surface of the body) endoscopic procedure, is increasingly being performed to assist in the management of certain groups of patients with gastroparesis.

This data will be used for research purposes only to determine the clinical impact of endoscopic treatments on gastroparesis. The physicians will also be able to better understand the patient's condition and disease process that may lead to improved standard of care and improved patient management.

03

Conditions studied

  • Gastroparesis

Browse trials for

Keywords

  • GPOEM
  • Gastric Per-Oral Endoscopic Myotomy
  • Myotomy
  • Gastroparesis
  • g-poem
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

As long as patients fall under the inclusion criteria and do not fall under exclusions, every patient can be considered. Patient must be declared safe to undergo procedure on individual basis from an evaluation from head doctor on study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age
  • Referral for endoscopic treatment of Gastroparesis for symptom management

Exclusion criteria

Exclusion Criteria:

  • \< 18 years of age
  • Absence of gastroparesis based on scintigraphy studies
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Assessment of Change in Gastroparesis Cardinal Symptom Index (GCSI) from baseline to post G-POEM

    The Gastroparesis Cardinal Symptom Index (GCSI) is used for assessing severity of symptoms associated with gastroparesis. Patients are to score each of the 9 symptom criteria on 0 (None) to 5 (Very Severe) Likert Scale. The higher the score the more symptomatic from gastroparesis the patient is. Nausea or Vomiting (score 0-5 for each of the following 3 criteria) * Nausea * Retching * Vomiting Postprandial fullness or early satiety (score 0-5 for each of the following 4 criteria) * Stomach Fullness * Not able to finish a normal-sized meal * Feeling excessively full after meals * Loss of appetite Bloating (score 0-5 for each of the following 2 criteria) * Bloating * Stomach visibly larger

    Time frame: 60 months span: baseline and assess change at 1 month, 3 month, 6 month, 12 month, 24 month, 36 month, 48 month & 60 months

  2. Assessment of Change in Patient Assessment of gastrointestinal disorders-symptom severity index (PAGI-SYM) score from baseline to post G-POEM

    Change in PAGI-Sym score: The PAGI-SYM is composed of 20 items and 6 subscales: heartburn/regurgitation (7 items), nausea/vomiting (3 items), postprandial fullness/early satiety (4 items), bloating (2 items), upper abdominal pain (2 items), and lower abdominal pain (2 items). Subscale scores are calculated by averaging across items comprising the subscale; scores vary from 0 (none or absent) to 5 (very severe)

    Time frame: 60 months span: baseline and assess change at 1,3,6,12,24, 36,48 & 60 months

  3. Assessment of Change in G-POEM SF-36 Health Survey score from baseline to post G-POEM

    Change in health belief questionnaire (SF-36) score: Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability and the higher scores indicate better health

    Time frame: baseline and assess change at 1,3,6,12,24,36,48 & 60 months

  4. Assessment of change in Gastric Emptying Scan (GES) (solid phase, 4 hour study) from baseline to post G-POEM

    we will track change in GES at 6 months and 24 months post G-POEM and compare to baseline. Normal GES should have under 5% at 4 hours

    Time frame: baseline; and assess change at 6, and 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ichkhanian Y, Salame M, Wo JM, Nowak TV, Stainko S, Saito A, Siwiec RM, Kais A, Hwang JH, Li AA, Yang J, Broucek JR, Esfandyari T, Joseph S, Ujiki MB, Williams AE, Moremen J, Gouda Z, Schlachterman A, Hugova K, Martinek J, Geng CX, Podboy A, Wang AY, Lajin M, Gregor L, Miller PM, Al Bunni H, DeWitt JM, Al-Haddad M. A New International Scheme for the Classification and Management of Clinical Outcomes Post-gastric Peroral Endoscopic Myotomy. Clin Gastroenterol Hepatol. 2025 Dec;23(13):2477-2487.e1. doi: 10.1016/j.cgh.2025.03.022. Epub 2025 May 14. PubMed 40378985 ↗
  • Salame M, Ichkhanian Y, Hadaki N, Wo JM, Stainko SA, Saito A, Siwiec RM, Nowak TV, Li A, Hwang JH, Yang J, Broucek J, Esfandyari T, Joseph S, Ujiki M, Williams AE, Moremen JR, Gouda Z, Schlachterman A, Hugova K, Martinek J, Geng CX, Podboy A, Wang AY, Lajin M, Miller P, Gregor L, Albunni H, Dewitt JM, Al-Haddad MA. Safety of same-day discharge after gastric peroral endoscopic myotomy in patients with refractory gastroparesis: an international multicenter study. Gastrointest Endosc. 2025 Oct;102(4):595-599.e1. doi: 10.1016/j.gie.2025.02.020. Epub 2025 Feb 19. PubMed 39983999 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Aug 2026, 96 months after the start.

Of 47 observational studies under Gastroparesis, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 142. This study's planned 96 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2018
First posted
Jun 17, 2020
StartActual
Aug 7, 2018
Primary completionEst.
Aug 15, 2026
CompletionEst.
Aug 15, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04434781
Lead sponsor
Indiana University
Responsible party
Mohammad Al-Haddad (Associate Professor of Medicine, Associate Clinical Director, Indiana University) — Principal investigator
First posted
Jun 17, 2020
Start date
Aug 7, 2018
Primary completion
Aug 15, 2026 (estimated)
Completion
Aug 15, 2026 (estimated)
Last update
Feb 18, 2026

Study contacts

Jacque Peterman
Contact
petermaj@iu.edu
317-944-0980
Mohammad Al-Haddad, MD
Contact
moalhadd@iu.edu
317-944-0980
Mohammad Al-Haddad, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion